Monoclonal antibodies in acute lymphoblastic leukemia.

  title={Monoclonal antibodies in acute lymphoblastic leukemia.},
  author={Elias J Jabbour and Susan M O'Brien and Farhad Ravandi and Hagop M Kantarjian},
  volume={125 26},
With modern intensive combination polychemotherapy, the complete response (CR) rate in adults with acute lymphoblastic leukemia (ALL) is 80% to 90%, and the cure rate is 40% to 50%. Hence, there is a need to develop effective salvage therapies and combine novel agents with standard effective chemotherapy. ALL leukemic cells express several surface antigens amenable to target therapies, including CD20, CD22, and CD19. Monoclonal antibodies target these leukemic surface antigens selectively and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 41 times over the past 90 days. VIEW TWEETS
35 Citations
54 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 35 extracted citations


Publications referenced by this paper.
Showing 1-10 of 54 references

Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

  • MS Topp, N Goekbuget, AS Stein
  • Lancet Oncology
  • 2015
1 Excerpt

Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients and as For personal use

  • E Jabbour, S O’Brien, J Nitin
  • only. on May 25,
  • 2015
2 Excerpts

Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular For personal use

  • M Topp, N Gokbuget, G Zugmaier
  • only. on May
  • 2015
1 Excerpt

Southwest Oncology Group Study S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukemia

  • A Advani, S McDonough, S Coutre
  • Br J Haematol
  • 2015
1 Excerpt

Augmented Berlin-Frankfurt-Muenster based therapy for young adults with acute lymphoblastic leukemia

  • M Rytting, DA Thomas, S O’Brien
  • (ALL). Cancer
  • 2014
1 Excerpt

Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD20 positive acute lymphoblastic leukemia

  • E Jabbour, H Kantarjian, D Thomas
  • J Clin Oncol
  • 2014
2 Excerpts

Similar Papers

Loading similar papers…